TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34607196
Drug: Control (pure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (pure virgin olive oil, 20 ml once daily for 30 months)
Study: 35172891
Drug: Intravenous imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous imatinib mesylate 200 mg bis in die (b.i.d.) for 7 days
Study: 35172891
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV infusion for 7 days
Study: 32696258
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 μg/kg/h IV infusion for 24 h)
Study: 32696258
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 μg/kg/h IV infusion for 24 h)
Study: 35183168
Drug: Subsidized eyeglasses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsidized eyeglasses provided to myopic children in treatment schools
Study: 35183168
Drug: Prescription information
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription information provided without subsidized eyeglasses in control schools
Study: 32727831
Drug: Sequential Xpert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Xpert followed by LAM
Study: 32727831
Drug: Concurrent testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent testing with LAM + Xpert
Study: 32727831
Drug: Cost per
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost per TB case diagnosed for sequential and concurrent strategies
Study: 34905482
Drug: Low-intensity magnetic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity magnetic stimulation (LIMS) plus standard pharmacological treatment
Study: 34534858
Drug: CBT-T (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-T (Cognitive Behaviour Therapy emphasizing early behaviour change and body image improvement)
Study: 34534858
Drug: CBTm (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBTm (Cognitive Behaviour Therapy including motivational work and no body image content)
Study: 32495666
Drug: Permethrin 5%
Normalized name: PERMETHRIN 5% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin 5% cream applied on two occasions within a one-week interval (Group A)
Study: 32495666
Drug: Intensive application
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive application of permethrin 5% cream (Group B)
Study: 36364742
Drug: NO3−/NO2− supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO3−/NO2− supplementation (beetroot juice containing 250 mg nitrate and 20 mg nitrite/day)
Study: 32562684
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg PD01A
Study: 32562684
Drug: 75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 μg PD01A
Study: 32562684
Drug: Booster immunisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster immunisation (75 μg)
Study: 32562684
Drug: Systemic treatment-related
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment-related adverse events
Study: 32568400
Drug: Nocturnal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal oxygen therapy (NOT) administered at 3 L/min by nasal cannula during nights at 2048 m
Study: 32568400
Drug: Placebo (room
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (room air) administered during nights at 2048 m
Study: 35902817
Drug: SARS‐CoV‐2 vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS‐CoV‐2 vaccines (first two licensed in Switzerland)
Study: 34974277
Drug: Kinesio Taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio Taping (KT) plus Oral-Motor Training (OMT)
Study: 34974277
Drug: Sham Taping
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Taping plus Oral-Motor Training (OMT)
Study: 33151187
Drug: Both TR
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both TR and free-hand implants
Study: 33762428
Drug: Epigallocatechin‐3‐gallate (EGCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epigallocatechin‐3‐gallate (EGCG) 800 mg daily for 18 months
Study: 34951974
Drug: IDA (Intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDA (Intradermal Adaptor)
Study: 33069301
Drug: Cytisine (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytisine (9 mg on day 0, gradually reduced to 1.5 mg by day 25)
Study: 36195897
Drug: Social norm
Normalized name: K Norm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social norm feedback on antibiotic prescribing
Study: 36195897
Drug: Social norm
Normalized name: K Norm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social norm feedback plus online peer-moderated training on rational antibiotic prescribing, communication strategies, and sustainable behavior change
Study: 34830709
Drug: Internal conical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal conical connection implants
Study: 34830709
Drug: Internal hexagonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal hexagonal connection implants
Study: 35426033
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg capsule for 14 days during each chemotherapy cycle
Study: 35426033
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 14 days during each chemotherapy cycle
Study: 33250314
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day Oligopin®
Study: 35936217
Drug: Acetyl-L-Carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-Carnitine (ALC) 1000 mg three times per day for three consecutive days
Study: 35445808
Drug: Combined CPAP
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined CPAP and tolterodine treatment
Study: 35445808
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment only
Study: 39699848
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine U300
Study: 34051544
Drug: Immediate reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate reduction from 15.5 to 0.4 mg of nicotine per gram of tobacco (mg/g)
Study: 34051544
Drug: Gradual reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual reduction to 0.4 mg/g
Study: 34051544
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with normal nicotine cigarettes (15.5 mg/g)
Study: 34328109
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (500 mg capsule containing Lactobacillus acidophilus LA1, Bifidobacterium longum sp54 cs, and Bifidobacterium bifidum sp9 cs)
Study: 32214139
Drug: Epidural bolus
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bolus (0.15% ropivacaine 0.3 ml·kg‐1)
Study: 32214139
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (0.15% ropivacaine 0.3 ml·kg‐1)
Study: 32070793
Drug: Early Manual
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Manual Therapy Group (EMTG)
Study: 36343423
Drug: Rosemary capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosemary capsules, 1 capsule twice a day for 8 weeks
Study: 36343423
Drug: Placebo, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 capsule twice a day for 8 weeks
Study: 33066761
Drug: Pyridostigmine bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine bromide 60 mg/day P.O.
Study: 35039300
Drug: LEGO-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEGO-based therapy
Study: 34362303
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg 10% IVIG administered every two weeks for five doses
Study: 34362303
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline administered every two weeks for five doses (control)
Study: 35550645
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT-SAD)
Study: 34018057
Drug: Machine Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine Learning (ML) using a random forest algorithm trained on 10 features extracted from ultrasound images.
Study: 34018057
Drug: Machine Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine Learning (ML) aiding a breast radiologist.
Study: 34018057
Drug: Breast radiologist
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast radiologist without ML assistance.
Study: 35686864
Drug: Combined ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ultrasound guided peritendinous hyaluronic acid (HA) injection with extracorporeal shock waves therapy (E‐g)
Study: 35686864
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock waves therapy only (SC‐g)
Study: 33616478
Drug: HL02 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL02 (6 mg/kg)
Study: 32422942
Drug: UDCA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA treatment (100 mg three times per day for two months)
Study: 33044102
Drug: Acarbose test
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose test formulation (T)
Study: 33683313
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic blood pressure goal <120 mm Hg)
Study: 33683313
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (systolic blood pressure goal <140 mm Hg)
Study: 33683313
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between intensive and standard treatment
Study: 36229224
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rhEpo) treatment, 9 IU × kg bw−1, injected three times per week for 4 weeks
Study: 36229224
Drug: Blood transfusions,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood transfusions, 130 ml red blood cells infused
Study: 34663787
Drug: Engage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engage therapy
Study: 33813244
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of sucrose (S10)
Study: 33813244
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of sucrose (S15)
Study: 35997816
Drug: CC (Usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (Usual Community Care)
Study: 35064876
Drug: Subjective titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjective titration
Study: 35064876
Drug: PSG-guided titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSG-guided titration using RCMP
Study: 35064876
Drug: DISE-assisted titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: DISE-assisted titration using RCMP
Study: 36120593
Drug: OEA 300
Normalized name: OEA
DrugBank: Oleic monoethanolamide (DB16495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OEA 300 mg/day
Study: 36120593
Drug: OEA 600
Normalized name: OEA
DrugBank: Oleic monoethanolamide (DB16495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OEA 600 mg/day
Study: 34498388
Drug: BISO/RAMI 10/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BISO/RAMI 10/5 mg
Study: 34498388
Drug: BISO/RAMI 10/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BISO/RAMI 10/10 mg
Study: 34498388
Drug: BISO 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BISO 10 mg and RAMI 10 mg (single doses)
Study: 33928903
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (loading dose 1 g over 10 minutes then infusion of 1 g over 8 hours)
Study: 32529206
Drug: Oily fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oily fish (∼300 g/wk)
Study: 34717041
Drug: givosiran (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: givosiran (2.5 mg/kg monthly)
Study: 33052789
Drug: Topical scar
Normalized name: Mederma Advanced Scar Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical scar gel containing Allium cepa extract, allantoin and heparin, applied postoperatively for 6 months.
Study: 35259918
Drug: Invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive treatment strategy (INV)
Study: 35292055
Drug: Qingre Lishi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingre Lishi Decoction (QLRD) - 'heat-clearing and diuresis-promoting' prescription
Study: 35292055
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment and colchicine tablets (Control)
Study: 34813986
Drug: Fully Integrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully Integrated Treatment (FIT) for comorbid SAD and AUD IOP
Study: 33789524
Drug: H1-receptor antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H1-receptor antagonists (H1RAs)
Study: 33091192
Drug: On-demand inhaled
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand inhaled interferon beta-1a (AZD9412)
Study: 35872235
Drug: IVPCA (Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVPCA (Intravenous Patient-Controlled Analgesia)
Study: 35872235
Drug: On-demand administration
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand administration (oral, intramuscular, or intravenous)
Study: 34183341
Drug: TRiP(cast) score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRiP(cast) score based thromboprophylactic anticoagulant treatment for patients with a score ≥7
Study: 35819423
Drug: Pharmacogenomic-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenomic-guided treatment (n=966)
Study: 35819423
Drug: Pharmacogenomic-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenomic-guided treatment
Study: 36100350
Drug: Continuous ixekizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ixekizumab treatment
Study: 34750069
Drug: Twice per
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice per week heat training (HT2)
Study: 32635999
Drug: Regular clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular clinical treatment for OA
Study: 34975131
Drug: Dexmedetomidine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.75 μg/kg intravenous over 10 min
Study: 34975131
Drug: Midazolam 0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.035 mg/kg intravenous over 1 min
Study: 39511836
Drug: Testosterone Replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone Replacement Therapy (TRT)
Study: 35085506
Drug: Pyrotinib 400
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib 400 mg orally once daily and capecitabine 1000 mg/m2 orally twice daily for 14 days, followed by 7 days off every 3 weeks until disease progression or unacceptable toxicity.
Study: 34756613
Drug: 2008-2009 seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2008-2009 seasonal inactivated trivalent influenza vaccine (TIV)
Study: 34756613
Drug: Control hepatitis
Normalized name: hepatitis A virus strain CR 326F antigen, inactivated Injection [Vaqta]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control hepatitis A (HepA) vaccine
Study: 35966870
Drug: Intrathecal pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal pethidine (10 mg) with bupivacaine (12.5 mg)
Study: 35966870
Drug: Bupivacaine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (12.5 mg) alone
Study: 33438085
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (100 mL of orange juice with 12 g carrot and 2.5 g of turmeric) three times per week for three months
Study: 33400078
Drug: Supplemental education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental education explaining the rationale behind recommendations to delay fertility treatments due to the COVID‐19 pandemic
Study: 32201918
Drug: Body weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body weight-based prednisolone regimen (2 mg/kg/day till remission, then 1.5 mg/kg on alternate days for 4 weeks)
Study: 32201918
Drug: Body surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body surface area-based prednisolone regimen (60 mg/m2/day till remission, then 40 mg/m2 on alternate days for 4 weeks)
Study: 35487525
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg orally for 6 months
Study: 34950731
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (1.5 g, LCG)
Study: 34950731
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose (3.0 g, MCG)
Study: 34950731
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (6.0 g, HCG)
Study: 34950731
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (1.5 g, 3.0 g, 6.0 g)
Study: 33753432
Drug: Integration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integration of a pharmacist within general practice teams to optimise prescribing and medication-related activities.
Study: 32366238
Drug: Self-medication behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-medication behavior
Study: 32366238
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of OTC drugs
Study: 32366238
Drug: Awareness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness of risks of self-medication
Study: 32366238
Drug: Health issues
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health issues leading to self-medication
Study: 32366238
Drug: Types of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Types of medication used
Study: 32366238
Drug: Sources of
Normalized name: Dental Resources brand of Stannous Fluoride Dental Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sources of self-medication
Study: 32366238
Drug: Risk factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk factors for self-medication
Study: 37349694
Drug: Tolvaptan treatment
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan treatment
Study: 32166429
Drug: Leflunomide (LEF)
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide (LEF) 20 mg daily
Study: 33693561
Drug: Ruxolitinib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (10 mg twice daily) plus stable ART for 5 weeks
Study: 33190008
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg per day sumac powder for 12 weeks
Study: 35972010
Drug: Topical khat
Normalized name: KHAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical khat leaves
Study: 33753456
Drug: fam-trastuzumab deruxtecan-nxki
Normalized name: fam-trastuzumab deruxtecan-nxki
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: fam-trastuzumab deruxtecan-nxki (T-DXd) at a dose of 5.4 mg/kg
Study: 32460697
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral care intervention (weekly)
Study: 32804611
Drug: Glucocorticoids treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids treatment in patients with initial C-reactive protein (CRP) ≥20 mg/dL
Study: 32804611
Drug: Glucocorticoids treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids treatment in patients with CRP <10 mg/dL
Study: 32634760
Drug: Dose-dense (DD)
Normalized name: DDS
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-dense (DD) chemotherapy
Study: 32634760
Drug: Standard-interval (SI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-interval (SI) chemotherapy
Study: 39141378
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg)
Study: 36273478
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose of antenatal betamethasone
Study: 36273478
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of antenatal betamethasone
Study: 35658325
Drug: Minodronate 1
Normalized name: Minodronate
DrugBank: Minodronic acid (DB06548)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Minodronate 1 mg with 500 mg calcium and 200 U vitamin D3
Study: 35658325
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 500 mg calcium and 200 U vitamin D3
Study: 34961905
Drug: Phase III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase III liquid formulation by autoinjector (Treatment A)
Study: 34961905
Drug: Phase I/II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I/II reconstituted lyophilizate-based formulation by syringe (Treatment C)
Study: 34961905
Drug: Phase III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase III liquid formulation by prefilled syringe (Treatment B)
Study: 33464993
Drug: Other drug
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drug use screening
Study: 33755582
Drug: Vi‐tetanus toxoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi‐tetanus toxoid conjugate vaccine (Typhoid Vaccine Acceleration Consortium: TyVAC)